查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1466375

免疫检测市场：按产品、技术、检体、适应症和最终用户 - 2024-2030 年全球预测

Immunoassay Market by Product (Analyzer, Consumables), Technology (Chemiluminescence Immunoassay, Enzyme-linked Immunosorbent Assay, Fluoroimmunoassay), Specimen, Indication, End User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年免疫检测市场规模为263亿美元，预计2024年将达282.9亿美元，2030年将达429亿美元，复合年增长率为7.24%。

免疫检测是一种灵敏且特异性的生化技术，用于定量和检测各种分子，包括蛋白质、荷尔蒙、抗体和其他生物学相关物质。免疫检测市场的成长是由多种因素推动的，例如慢性病盛行率的增加、个人化医疗需求的增加、免疫检测在肿瘤诊断中的广泛使用以及技术进步导致准确性和高通量性能的提高。此外，由于对快速检测解决方案的需求激增，COVID-19 大流行也对该市场的成长做出了重大贡献。然而，先进免疫检测系统的高成本可能会阻碍其在小型实验室和资源有限的环境中的采用。此外，严格的产品核可监管指南可以延长新产品的上市时间。为了克服这些挑战并维持免疫检测市场的业务成长，公司正在创建具有成本效益的解决方案，以满足全球各种医疗保健环境中更广泛的用户群，我们正在探索技术创新和研究的可能性，例如专注于。此外，我们也与学术机构和研究中心合作，促进检测设计的突破性创新，针对现有产品目前无法解决的新型分析物和应用。除此之外，市场参与企业正在开发用于早期疾病检测的新型生物标记物，从而扩大免疫检测的临床应用。

主要市场统计
基准年[2023] 263亿美元
预测年份 [2024] 282.9亿美元
预测年份 [2030] 429亿美元
复合年增长率（%） 7.24%

产品开发用于诊断感染疾病和自体免疫疾病的新型免疫检测套件

分析仪是免疫检测的核心，有助于检测和测量检体中的目标分析物。这些分析仪用于临床实验室、医院、製药公司和研究机构，用于筛检各种生物标记并检测特定分析物，如荷尔蒙、蛋白质和病原体。因此，对具有快速週转时间、高通量和易于使用的介面的分析仪的需求不断增长。为了满足这些需求，製造商正在引入创新技术，例如基于化学冷光的检测系统、多重检测和先进的软体解决方案，以提高效率并提供准确的结果。

耗材在免疫检测中发挥至关重要的作用，透过高品质的试剂、套件和其他一次性物品来确保可靠的测试结果。在消耗品中，试剂透过促进抗体和抗原之间的特异性结合相互作用，在进行免疫检测中发挥重要作用。试剂包括一抗、二抗、酵素标结合物、基材、缓衝液和其他必要的化学物质。这些试剂的性能特征直接影响测定的可靠性和重现性。免疫检测套件由一组预先包装的试剂以及用于执行特定测定的详细方案组成。易用性、标准化和优化性能等优点正在推动世界各地实验室对即用型套件的需求。孔盘和管子作为各种免疫检测的支撑结构，透过允许同时分析多个样品来提供可扩展性和高通量能力。其材料成分在最大限度地减少特异性结合同时保持分析物检测的最佳条件方面发挥着重要作用。

技术 利用酵素结合免疫吸附测定技术治疗食物过敏及药物滥用

化学冷光免疫检测(CLIA) 是一种灵敏且特异性的技术，透过化学反应发出的光来测量分析物的浓度。 CLIA 最近因其高通量、快速结果和良好的信噪比而受到欢迎，有利于检测低丰度生物标记、感染疾病和荷尔蒙水平。酵素连结萤光测定 (ELFA) 使用酵素连结抗体和萤光基材来定量特定分析物。 ELFA 可在相对较小的样品量中提供具有高灵敏度和特异性的快速分析。该技术可用于多种应用，包括感染疾病诊断、自体免疫疾病检测和治疗药物监测。酵素结合免疫吸附检测法(ELISA) 广泛用于诊断和研究应用，以检测蛋白质、胜胜肽、荷尔蒙和抗体。 ELISA 具有高灵敏度、特异性和重现性，并且可轻鬆适应微孔盘和以微珠为基础的形式。免疫检测是一种使用放射性同位素检测生物样本中目标分子的成熟技术。儘管随着非放射性技术的出现，RIA 的受欢迎程度有所下降，但 RIA 在某些利基应用中仍然具有重要意义，例如测量低水平激素、药物监测和评估受体结合研究。快速诊断测试是即时检测设备，可以从血液或尿液等检体中快速获得结果，而不需要专门的测试设备或人员。这些测试已成为资源有限环境中感染疾病诊断、怀孕和药物滥用筛检的重要工具。

使用非侵入性检体采集方法进行唾液诊断的出现

免疫检测检体的选择取决于多种因素，例如感兴趣的疾病类型、生物标记的可用性、检体采集的难易程度以及患者的舒适度。血液通常是免疫检测的检体，因为它可以全面了解个人的健康状况。血液通常用于检测感染疾病、癌症生物标记、荷尔蒙水平、自体免疫疾病等。唾液因其非侵入性采集方法以及易于储存和运输普及流行的血液检体，特别是在检测荷尔蒙水平、药物滥用测试、识别口腔病原体和评估整体口腔健康方面有用。尿液也是免疫检测中常用的检体，因为它采用非侵入性收集方法，并且能够检测多种分析物，例如滥用药物、怀孕荷尔蒙、肾功能标记和尿道感染指标。

优化免疫检测技术以满足感染疾病适应症不断增长的需求

由于全球心血管疾病 (CVD) 的高发生率，循环系统成为免疫检测市场的关键部分。根据世界卫生组织 (WHO) 统计，每年约有 1,790 万人死于心血管疾病，使其成为全球主要死亡原因。免疫检测在各种心臟疾病的诊断和监测中发挥重要作用，例如心肌梗塞、心臟衰竭和其他相关疾病。特别是，肌钙蛋白等生物标记对于评估出现胸痛和其他提示心肌缺血症状的患者的急性冠状动脉症候群至关重要。糖尿病、甲状腺功能障碍和荷尔蒙失衡等内分泌疾病在全球范围内不断增加。免疫检测透过准确定量患者检体中的荷尔蒙水平来满足这一需求。感染疾病是免疫检测市场的另一个重要领域。因为全世界对细菌、病毒和真菌感染的担忧与日俱增。 COVID-19 大流行进一步凸显了快速、准确的诊断工具对于识别和监测感染疾病传播的重要性。免疫检测对于检测特定病原体和免疫系统响应感染而产生的抗体非常有价值，从而可以及时采取干预和遏制措施。在肿瘤学中，免疫检测对于癌症筛检、诊断和监测治疗效果至关重要。免疫检测检测钙胚抗原（CEA）和前列腺特异性抗原（PSA）等肿瘤生物标记物，帮助临床医师对各种恶性进行早期检测、分期和预后评估，指导针对患者制定治疗策略。在整形外科领域，免疫检测用于监测骨骼代谢标记物，如 i 型前胶原蛋白N 端胜肽(胜肽 ) 和C 端交联端肽(CTX)，对骨质疏鬆症和其他骨相关疾病的诊断很有帮助。

最终用户：急诊医学、加护病房和门诊诊所对免疫检测的需求不断增加

由于输血和血液製品的需要，血库在免疫检测市场中扮演重要角色。免疫检测用于筛检捐赠者血液样本中是否有爱滋病毒、B型肝炎、C型肝炎和梅毒等感染疾病。从这些测试中获得的结果有助于确保血液供应在用于输血之前的安全。诊断实验室使用免疫检测进行常规医学测试，以检测生物样本中存在的各种生物标记。它有助于癌症、糖尿病、心血管疾病和其他慢性疾病的早期诊断。食品和饮料行业需要免疫检测来检测食品中的过敏原以及原材料和最终产品中的农药和毒素等污染物。食品和饮料製造商需要检测极限低的可靠方法，以满足监管要求并确保消费者安全。医院是免疫检测市场的关键最终用户部分之一，因为它们在多个部门广泛使用这些分析方法进行诊断，包括急诊医学、加护病房和门诊诊所。免疫检测有助于快速诊断和监测患者的各种疾病和状况，使医疗保健专业人员能够就患者的治疗计划做出明智的决定。製药公司和委外研发机构(CRO) 在药物发现、研究和开发以及临床试验过程中使用免疫检测。另一方面，研究和学术实验室需要免疫检测来进行涉及讯号传导途径和蛋白质-蛋白质相互作用的基础研究，以及疫苗开发和疾病监测计划等应用研究计划。

区域洞察

在美国和加拿大，癌症和心血管疾病等慢性疾病的盛行率不断上升，推动了对免疫检测的需求。这些国家医疗保健支出的增加也伴随着对疾病早期发现的日益关注。实验室正大力投资酵素结合免疫吸附检测法（ELISA）和化学冷光检测法（CLIA）等先进技术。除此之外，最近在该领域申请的专利还包括提高检测灵敏度和特异性，同时减轻交叉反应问题。在欧盟国家中，由于消费者健康意识的提高，中东和非洲地区的免疫检测市场正经历显着成长。由政府和医疗机构主导的倡议正在增加对诊断服务的公共投资。新兴市场的主要参与者正在专注于开发满足特定区域客户需求的新产品。印度和中国等亚太地区的新兴经济体面临着医疗费用上涨、慢性病患病率上升、需要诊断检测服务、实验室基础设施改善以及早期疾病检测意识增强等问题，这为医疗保健行业创造了巨大的免疫检测机会。此外，针对新兴市场特定疾病模式的产品客製化有助于扩大核心概况。此外，地方政府推出了多项倡议，以促进创新诊断开发的官民合作关係，为学术机构和私人企业提供支援和投资。

FPNV定位矩阵

FPNV定位矩阵对于评估免疫检测市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对免疫检测市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

该报告对以下几个方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.免疫检测市场的市场规模与预测是多少？

2.在免疫检测市场的预测期间内，有哪些产品、细分市场、应用和领域需要考虑投资？

3.免疫检测市场的技术趋势和法规结构是什么？

4.免疫检测市场主要厂商的市场占有率为何？

5. 进入免疫检测市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病和感染疾病的增加以及早期诊断的好处
      • 免疫检测在食品和饮料行业中的使用增加
      • 多重检测技术在药物研发的新应用
    • 抑制因素
      • 与免疫检测相关的交叉反应问题
    • 机会
      • 与免疫检测相关的自动化仪器和设备数量的技术进步
      • 免疫检测在环境监测中的巨大潜力
    • 任务
      • 由于样品品质和试剂性能的变化而导致的测定检验问题
  • 市场区隔分析
    • 产品：开发用于诊断感染疾病和自体免疫疾病的新型免疫检测套件
    • 技术：利用酵素结合免疫吸附测定技术治疗食物过敏和药物滥用
    • 检体：使用非侵入性采集方法进行唾液诊断的出现
    • 适应症：优化免疫检测技术以整体感染疾病不断增长的需求
    • 最终用户：急诊医学、加护病房和门诊诊所对免疫检测的需求正在增加
  • 市场趋势分析
    • 介绍一种由政府资助的新型永续免疫检测，旨在扩大美洲的免疫检测
    • 亚太地区感染疾病和自体免疫疾病的流行以及对高效医疗解决方案日益增长的需求
    • 随着政府对更多采用免疫检测的支持的增加，医疗保健公司正在增加其在欧洲、中东和非洲地区的业务。
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法规结构分析

第六章免疫检测市场：副产品

  • 分析仪
  • 消耗品

第七章免疫检测市场：依技术分类

  • 化学冷光免疫检测
  • 酵素免疫分析法
  • 萤光免疫分析
  • 免疫检测
  • 快速诊断测试 (RDT)/侧流免疫检测

第八章免疫检测市场（按样本）

  • 血
  • 唾液
  • 尿

第九章按适应症分類的免疫检测市场

  • 心臟病学
  • 内分泌学
  • 感染疾病
  • 肿瘤学
  • 整形外科

第 10 章免疫检测市场：依最终使用者分类

  • 血库
  • 诊断实验室
  • 食品和饮料公司
  • 医院
  • 製药公司和 CRO
  • 研究/学术机构

第十一章：美洲免疫检测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太免疫免疫检测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲的免疫检测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Thermo Fisher 斥资 31 亿美元收购 Olink，扩大蛋白质体学业务
    • FUJIREBIO和 Sysmex 合作开发独特的免疫检测方法
    • 迈瑞同意收购德国 Diasys 诊断系统公司 75% 的股份
    • CVC基金「岛津未来创新基金」投资了开发免疫检测技术的IMMUNOSENS Co., Ltd.。
    • Fapon推出新型化学冷光系统
    • Beckman Coulter 的 DxI 9000免疫检测分析仪具有改进的分析开发灵敏度，在 2023 年 AACC 北美首次亮相
    • 贝克曼库尔特 (Beckman Coulter) 和FUJIREBIO合作，增强患者友善血液阿兹海默症检测的可及性
    • Makati Med 成为菲律宾和东协第一家购买 Atelica VTLi 病患侧免疫检测的医院
    • QuidelOrtho Sofia 2 SARS 抗原+FIA 获得 FDA De Novo 批准
    • SGS 在普瓦捷实验室提供增强型自动化免疫检测测试
    • 西门子建立免疫检测仪器研发卓越中心

第15章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-43127F7279BC

[194 Pages Report] The Immunoassay Market size was estimated at USD 26.30 billion in 2023 and expected to reach USD 28.29 billion in 2024, at a CAGR 7.24% to reach USD 42.90 billion by 2030.

An immunoassay is a highly sensitive and specific biochemical technique used to quantify or detect a wide range of molecules, including proteins, hormones, antibodies, and other biologically relevant substances. The growth of the immunoassay market can be attributed to several influencing factors, such as the increasing prevalence of chronic diseases, rising demand for personalized medicine, expanding use of immunoassays in oncology diagnostics, and advancements in technology leading to higher throughput capabilities with improved accuracy. Moreover, the COVID-19 pandemic has also contributed significantly to the growth of this market due to the surge in demand for rapid testing solutions. However, high costs associated with advanced immunoassay systems may hamper their adoption by smaller laboratories or resource-limited settings. Additionally, stringent regulatory guidelines regarding product approvals can prolong the time to market for new products. To overcome these challenges and sustain business growth in the immunoassay market, organizations are exploring potential areas of innovation and research, including focusing on R&D efforts to create cost-effective solutions that cater to a wider user base across different healthcare settings worldwide. Additionally, collaborating with academic institutions and research centers to foster breakthrough innovations in assay design, targeting novel analytes or applications not currently addressed by existing products. Along with these, market participants are developing novel biomarkers for the early detection of diseases, leading to an expansion in clinical applications of immunoassays.

KEY MARKET STATISTICS
Base Year [2023] USD 26.30 billion
Estimated Year [2024] USD 28.29 billion
Forecast Year [2030] USD 42.90 billion
CAGR (%) 7.24%

Product: Development of novel immunoassay kits for diagnostics of infectious and autoimmune diseases

Analyzers are at the core of immunoassays as they facilitate the detection and measurement of target analytes in samples. These analyzers are typically used in clinical laboratories, hospitals, pharmaceutical companies, and research institutions to screen for various biomarkers and detect specific analytes such as hormones, proteins, and pathogens. There has been a growing need for analyzers with rapid turnaround times (TAT), high-throughput capabilities, and user-friendly interfaces. In response to these needs, manufacturers have introduced innovations such as chemiluminescence-based detection systems, multiplexed assays, and advanced software solutions to improve efficiency and provide accurate results.

Consumables play a critical role in immunoassays by ensuring reliable test results through high-quality reagents, kits, and other disposable items. In consumables, reagents play an essential role in performing immunoassays by facilitating specific binding interactions between antibodies and antigens. These include primary and secondary antibodies, enzyme-labeled conjugates, substrates, buffers, and other necessary chemicals. The performance characteristics of these reagents directly affect assay reliability and reproducibility. Immunoassay kits consist of a complete set of pre-packaged reagents, along with detailed protocols for conducting specific assays. Advantages such as ease of use, standardization, and optimized performance have increased demand for ready-to-use kits in laboratories worldwide. Microwell plates and tubes serve as support structures for various immunoassays, offering scalability and high-throughput capabilities by allowing multiple samples to be analyzed simultaneously. Their material composition plays a significant role in minimizing non-specific binding while maintaining optimal conditions for analyte detection.

Technology: Utilization of enzyme-linked immunosorbent assay technology for food allergies and drugs of abuse treatment

The chemiluminescence immunoassay (CLIA) is a highly sensitive and specific technology that measures the concentration of an analyte through the emission of light from a chemical reaction. CLIA has gained popularity recently due to its high throughput, rapid results, and favorable signal-to-noise ratios, which are beneficial in detecting low-abundance biomarkers, infectious diseases, and hormone levels. Enzyme-linked fluorescence assays (ELFA) involve using enzyme-labeled antibodies and fluorescent substrates to quantify specific analytes. ELFA provides a rapid analysis with high sensitivity and specificity while requiring relatively small sample volumes. This technology finds utility in various applications such as infectious disease diagnosis, autoimmune disorders detection, and therapeutic drug monitoring. Enzyme-linked immunosorbent assays (ELISA) are widely used in diagnostics and research applications to detect proteins, peptides, hormones, and antibodies. ELISA offers high sensitivity, specificity, and reproducibility with the convenience of being adaptable to both microplate and bead-based formats. Radioimmunoassay is a well-established technique that uses radioisotopes to detect target molecules in biological samples. Despite its declining popularity due to the emergence of non-radioactive techniques, RIA still holds relevance in specific niche applications such as the measurement of low-concentration hormones, drug monitoring, and assessment of receptor binding studies. Rapid diagnostic tests are point-of-care testing devices offering quick results from a sample such as blood or urine without requiring specialized laboratory equipment or personnel. These tests have become vital tools in diagnosing infectious diseases, pregnancy, and drug abuse screening in resource-limited settings.

Specimen: Emergence of saliva diagnostics due to its non-invasive collection methods

The choice of immunoassay specimen depends on factors such as the type of disease targeted, biomarker availability, ease of sample collection, and patient comfort. Blood is often the preferred specimen type for immunoassays due to its ability to provide comprehensive insights into an individual's health status. It is routinely used to detect infectious diseases, cancer biomarkers, hormone levels, and autoimmune disorders, among other applications. Saliva has emerged as a popular alternative to blood due to its non-invasive collection methods and ease of storage/transportation, which is particularly useful for detecting hormone levels, drug abuse testing, oral pathogens identification, and assessment of overall oral health status. Urine is another widely used specimen type in immunoassays due to its non-invasive collection procedure and ability to detect a wide range of analytes, such as drugs of abuse, pregnancy hormones, kidney function markers, and urinary tract infection indicators.

Indication: Optimization within immunoassay technologies to cater growing need across infectious disease

Cardiology is a major segment in the immunoassay market owing to the high prevalence of cardiovascular diseases (CVDs) worldwide. According to the World Health Organization, cardiovascular diseases account for approximately 17.9 million deaths annually, making it a major cause of mortality globally. Immunoassays play a critical role in diagnosing and monitoring various cardiac conditions such as myocardial infarction, heart failure, and other related disorders. In particular, biomarkers such as troponin are essential for evaluating acute coronary syndrome in patients presenting with chest pain or other symptoms suggestive of myocardial ischemia. Endocrine disorders like diabetes, thyroid dysfunction, and hormonal imbalances are increasingly affecting global populations. Immunoassays cater to this demand by accurately quantifying hormone levels in patients' samples. Infectious Disease represents another significant area within the immunoassay market due to widespread concerns over bacterial, viral, and fungal infections worldwide. The COVID-19 pandemic has further highlighted the importance of rapid and accurate diagnostic tools to identify and monitor the spread of infectious diseases. Immunoassays are valuable in detecting specific pathogens or antibodies produced by the immune system in response to infection, enabling timely intervention and containment measures. In Oncology, immunoassays have become indispensable for cancer screening, diagnosis, and monitoring treatment effectiveness. Immunoassays detect tumor biomarkers such as carcinoembryonic antigen (CEA) or prostate-specific antigen (PSA) that can aid clinicians in early detection, staging, and prognostic evaluation of various malignancies and guiding personalized therapeutic strategies for patients. In the field of orthopedics, immunoassays are used to monitor bone metabolism markers like procollagen type I N-terminal propeptide (PINP) and C-terminal cross-linking telopeptide (CTX), which assist in diagnosing osteoporosis and other bone-related disorders.

End User: Rising demand for immunoassay across emergency care, intensive care units, and outpatient clinics

Blood banks play a critical role in the immunoassay market due to the need for blood transfusions and blood-based products. Immunoassays are employed to screen for infectious diseases such as HIV, Hepatitis B and C, and syphilis in donor blood samples. The results obtained from these tests help ensure the safety of blood supplies before they are used for transfusion purposes. Diagnostic laboratories perform routine medical tests using immunoassays to detect different biomarkers present in biological samples. Across laboratories, assays aid in early diagnostics of diseases such as cancer, diabetes, cardiovascular disorders, and other chronic conditions. The food & beverage industry requires immunoassays for testing allergens in food products and contaminants, including pesticides and toxins in raw materials or finished goods. Food & beverage seek reliable methods with low detection limits to meet regulatory requirements and ensure consumer safety. Hospitals constitute one of the significant end-user segments of the immunoassay market due to their extensive use of these assays for diagnostic purposes across multiple departments, such as emergency care, intensive care units, and outpatient clinics. Immunoassays aid in the rapid diagnosis and monitoring of various diseases and conditions in patients, enabling healthcare professionals to make informed decisions regarding patient treatment plans. Pharmaceutical companies and contract research organizations (CROs) rely on immunoassays for drug discovery, development, and clinical trial phases. Whereas research & academic labs often need specialized immunoassays for basic research studies involving signaling pathways, protein-protein interactions, and applied research projects such as vaccine development and disease surveillance programs.

Regional Insights

In the Americas, the United States and Canada have witnessed a growing demand for immunoassays due to a rising prevalence of chronic diseases such as cancer and cardiovascular disorders. Increasing healthcare spending in these countries has also supplemented increased focus on early detection of diseases; laboratories are investing heavily in advanced technologies such as enzyme-linked immunosorbent assays (ELISA) and chemiluminescence immunoassays (CLIA). Apart from these, recent patents filed in this region encompass improvements in assay sensitivity and specificity while reducing cross-reactivity issues. In EU countries, the Middle East and Africa region has seen significant growth in the immunoassay market due to rising consumer health awareness. Initiatives led by governments and healthcare organizations have bolstered public investment in diagnostic services. Key players in this market focus on developing new products catering to specific regional customer requirements. Emerging countries across the Asia Pacific, such as India and China, present a considerable growth opportunity for immunoassay manufacturers due to increasing healthcare expenditure, rising prevalence of chronic diseases requiring diagnostic testing services, improving laboratory infrastructure, and growing awareness about early disease detection. Furthermore, customizing products to cater to specific disease patterns in emerging markets has helped expand key profiles. Additionally, the regional government has launched several initiatives to promote public-private partnerships in developing innovative diagnostic methods, providing support and investment for academic institutions and private enterprises.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Immunoassay Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Immunoassay Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Immunoassay Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies Inc., Almac Group Limited, ANP Technologies, Inc., Autobio Diagnostics Co., Ltd., Becton, Dickinson, and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, BioLegend, Inc., bioMerieux S.A., Biosurfit SA, Boditech Med Inc., Charles River Laboratories International, Inc., Danaher Corporation, Diasorin S.p.A., Dynex Technologies, Inc., Epitope Diagnostics Inc., F. Hoffmann-La Roche Ltd., Fapon Biotech Inc., Gyros Protein Technologies AB, H.U. Group Holdings Inc., J. Mitra & Co. Pvt. Ltd., Kamiya Biomedical Company, Koninklijke Philips N.V., Merck KGaA, MiCo BioMed, Inc., NanoEntek, Nanomix, Inc., OPKO Health, Inc., PerkinElmer, Inc., Promega Corporation, QIAGEN N.V., Quanterix Corporation, QuidelOrtho Corporation, Randox Laboratories Ltd., Shenzhen Micropoint Biotechnologies Co., Ltd., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthineers AG, Sysmex Corporation, Tecan Trading AG, Thermo Fisher Scientific Inc., Tosoh Corporation, WAK-Chemie Medical GmbH, Zoetis Inc., and Zybio Inc..

Market Segmentation & Coverage

This research report categorizes the Immunoassay Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Analyzer
    • Consumables
      • Assay Kits
      • Microwell Plates & Tubes
      • Reagents
  • Technology
    • Chemiluminescence Immunoassay
    • Enzyme-linked Immunosorbent Assay
    • Fluoroimmunoassay
    • Radioimmunoassay
    • Rapid Diagnostic Tests (RDTs)/Lateral Flow Immunoassay
  • Specimen
    • Blood
    • Saliva
    • Urine
  • Indication
    • Cardiology
    • Endocrinology
    • Infectious Disease
    • Oncology
    • Orthopedics
  • End User
    • Blood Banks
    • Diagnostics Laboratories
    • Food & Beverage Companies
    • Hospitals
    • Pharmaceutical Companies & CROs
    • Research & Academic Laboratories
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Immunoassay Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Immunoassay Market?

3. What are the technology trends and regulatory frameworks in the Immunoassay Market?

4. What is the market share of the leading vendors in the Immunoassay Market?

5. Which modes and strategic moves are suitable for entering the Immunoassay Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising chronic and infectious diseases and benefits of early diagnosis
      • 5.1.1.2. Growing usage of immunoassay in the food & beverage sector
      • 5.1.1.3. Emerging application of multiplex detection immunoassay technique in drug development
    • 5.1.2. Restraints
      • 5.1.2.1. Cross-reactivity issues associated with immunoassay
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in the number of automated instruments and equipment associated with immunoassay
      • 5.1.3.2. High potential of immunoassay in environment monitoring
    • 5.1.4. Challenges
      • 5.1.4.1. Issues with assay validation due to variations in sample quality and reagent performance
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Development of novel immunoassay kits for diagnostics of infectious and autoimmune diseases
    • 5.2.2. Technology: Utilization of enzyme-linked immunosorbent assay technology for food allergies and drugs of abuse treatment
    • 5.2.3. Specimen: Emergence of saliva diagnostics due to its non-invasive collection methods
    • 5.2.4. Indication: Optimization within immunoassay technologies to cater growing need across infectious disease
    • 5.2.5. End User: Rising demand for immunoassay across emergency care, intensive care units, and outpatient clinics
  • 5.3. Market Trend Analysis
    • 5.3.1. Introduction of novel sustainable immunoassays with government funding to scale up of immunoassays in the Americas
    • 5.3.2. Prevalence of infectious and autoimmune diseases, and rising need for efficient healthcare solution in the Asia-Pacific region
    • 5.3.3. Increasing support by government to expand adoption of immunoassay coupled with strong presence of healthcare companies in EMEA region
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis

6. Immunoassay Market, by Product

  • 6.1. Introduction
  • 6.2. Analyzer
  • 6.3. Consumables

7. Immunoassay Market, by Technology

  • 7.1. Introduction
  • 7.2. Chemiluminescence Immunoassay
  • 7.3. Enzyme-linked Immunosorbent Assay
  • 7.4. Fluoroimmunoassay
  • 7.5. Radioimmunoassay
  • 7.6. Rapid Diagnostic Tests (RDTs)/Lateral Flow Immunoassay

8. Immunoassay Market, by Specimen

  • 8.1. Introduction
  • 8.2. Blood
  • 8.3. Saliva
  • 8.4. Urine

9. Immunoassay Market, by Indication

  • 9.1. Introduction
  • 9.2. Cardiology
  • 9.3. Endocrinology
  • 9.4. Infectious Disease
  • 9.5. Oncology
  • 9.6. Orthopedics

10. Immunoassay Market, by End User

  • 10.1. Introduction
  • 10.2. Blood Banks
  • 10.3. Diagnostics Laboratories
  • 10.4. Food & Beverage Companies
  • 10.5. Hospitals
  • 10.6. Pharmaceutical Companies & CROs
  • 10.7. Research & Academic Laboratories

11. Americas Immunoassay Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Immunoassay Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Immunoassay Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Thermo Fisher to Acquire Olink for USD 3.1 billion, Expanding Proteomics Presence
    • 14.3.2. Fujirebio and Sysmex to Collaborate On Development of Unique Immunoassays
    • 14.3.3. Mindray Has Agreed to Acquire 75% Stake in Germany-Based DiaSys Diagnostic Systems GmbH
    • 14.3.4. CVC Fund "Shimadzu Future Innovation Fund" has Invested in IMMUNOSENS Co., Ltd., Developing Immunoassay Technology.
    • 14.3.5. Fapon Rolls Out New Chemiluminescence Immunoassay System
    • 14.3.6. Beckman Coulter's DxI 9000 Immunoassay Analyzer with Increased Assay Development Sensitivity Makes First North American Appearance at 2023 AACC
    • 14.3.7. Beckman Coulter and Fujirebio Partner to Bolster Access to Patient-friendly, Blood-based Alzheimer's Disease Test
    • 14.3.8. MakatiMed First PH and ASEAN Hospital to Acquire Atellica VTLi Patient-Side Immunoassay Analyzer
    • 14.3.9. QuidelOrtho Receives De Novo FDA Authorization for Sofia 2 SARS Antigen+ FIA
    • 14.3.10. SGS Offers Enhanced Automated Immunoassay Testing at Poitiers Laboratory
    • 14.3.11. Siemens launches Centre of Excellence for Immunoassay Instrument R&D

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. IMMUNOASSAY MARKET RESEARCH PROCESS
  • FIGURE 2. IMMUNOASSAY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL IMMUNOASSAY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. IMMUNOASSAY MARKET DYNAMICS
  • FIGURE 7. GLOBAL IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL IMMUNOASSAY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL IMMUNOASSAY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL IMMUNOASSAY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL IMMUNOASSAY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES IMMUNOASSAY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES IMMUNOASSAY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. IMMUNOASSAY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. IMMUNOASSAY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. IMMUNOASSAY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL IMMUNOASSAY MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNOASSAY MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNOASSAY MARKET SIZE, BY ANALYZER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNOASSAY MARKET SIZE, BY ANALYZER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNOASSAY MARKET SIZE, BY ASSAY KITS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNOASSAY MARKET SIZE, BY ASSAY KITS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNOASSAY MARKET SIZE, BY MICROWELL PLATES & TUBES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNOASSAY MARKET SIZE, BY MICROWELL PLATES & TUBES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNOASSAY MARKET SIZE, BY REAGENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNOASSAY MARKET SIZE, BY REAGENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL IMMUNOASSAY MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL IMMUNOASSAY MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL IMMUNOASSAY MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL IMMUNOASSAY MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL IMMUNOASSAY MARKET SIZE, BY FLUOROIMMUNOASSAY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNOASSAY MARKET SIZE, BY FLUOROIMMUNOASSAY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNOASSAY MARKET SIZE, BY RADIOIMMUNOASSAY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL IMMUNOASSAY MARKET SIZE, BY RADIOIMMUNOASSAY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL IMMUNOASSAY MARKET SIZE, BY RAPID DIAGNOSTIC TESTS (RDTS)/LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL IMMUNOASSAY MARKET SIZE, BY RAPID DIAGNOSTIC TESTS (RDTS)/LATERAL FLOW IMMUNOASSAY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL IMMUNOASSAY MARKET SIZE, BY BLOOD, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL IMMUNOASSAY MARKET SIZE, BY BLOOD, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL IMMUNOASSAY MARKET SIZE, BY SALIVA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL IMMUNOASSAY MARKET SIZE, BY SALIVA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL IMMUNOASSAY MARKET SIZE, BY URINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL IMMUNOASSAY MARKET SIZE, BY URINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL IMMUNOASSAY MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL IMMUNOASSAY MARKET SIZE, BY CARDIOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL IMMUNOASSAY MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL IMMUNOASSAY MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL IMMUNOASSAY MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL IMMUNOASSAY MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL IMMUNOASSAY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL IMMUNOASSAY MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL IMMUNOASSAY MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL IMMUNOASSAY MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL IMMUNOASSAY MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL IMMUNOASSAY MARKET SIZE, BY BLOOD BANKS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL IMMUNOASSAY MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL IMMUNOASSAY MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL IMMUNOASSAY MARKET SIZE, BY FOOD & BEVERAGE COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL IMMUNOASSAY MARKET SIZE, BY FOOD & BEVERAGE COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL IMMUNOASSAY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL IMMUNOASSAY MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL IMMUNOASSAY MARKET SIZE, BY PHARMACEUTICAL COMPANIES & CROS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL IMMUNOASSAY MARKET SIZE, BY PHARMACEUTICAL COMPANIES & CROS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. GLOBAL IMMUNOASSAY MARKET SIZE, BY RESEARCH & ACADEMIC LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 66. GLOBAL IMMUNOASSAY MARKET SIZE, BY RESEARCH & ACADEMIC LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 77. AMERICAS IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 78. AMERICAS IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 79. AMERICAS IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 80. AMERICAS IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 81. ARGENTINA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 82. ARGENTINA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 83. ARGENTINA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 84. ARGENTINA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 85. ARGENTINA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 86. ARGENTINA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 87. ARGENTINA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 88. ARGENTINA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 89. ARGENTINA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 90. ARGENTINA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 91. ARGENTINA IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 92. ARGENTINA IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 93. BRAZIL IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 94. BRAZIL IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 95. BRAZIL IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 96. BRAZIL IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 97. BRAZIL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 98. BRAZIL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 99. BRAZIL IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 100. BRAZIL IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 101. BRAZIL IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 102. BRAZIL IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 103. BRAZIL IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 104. BRAZIL IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 105. CANADA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 106. CANADA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 107. CANADA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 108. CANADA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 109. CANADA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 110. CANADA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 111. CANADA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 112. CANADA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 113. CANADA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 114. CANADA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 115. CANADA IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 116. CANADA IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 117. MEXICO IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 118. MEXICO IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 119. MEXICO IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 120. MEXICO IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 121. MEXICO IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 122. MEXICO IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 123. MEXICO IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 124. MEXICO IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 125. MEXICO IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 126. MEXICO IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 127. MEXICO IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 128. MEXICO IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 129. UNITED STATES IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 130. UNITED STATES IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 131. UNITED STATES IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 132. UNITED STATES IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 133. UNITED STATES IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 134. UNITED STATES IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 135. UNITED STATES IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 136. UNITED STATES IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 137. UNITED STATES IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 138. UNITED STATES IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 139. UNITED STATES IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 140. UNITED STATES IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 141. UNITED STATES IMMUNOASSAY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 142. UNITED STATES IMMUNOASSAY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 158. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 159. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 160. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 161. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 162. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 163. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 164. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 165. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 166. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 167. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 168. AUSTRALIA IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 169. CHINA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 170. CHINA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 171. CHINA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 172. CHINA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 173. CHINA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 174. CHINA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 175. CHINA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 176. CHINA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 177. CHINA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 178. CHINA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 179. CHINA IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 180. CHINA IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 181. INDIA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 182. INDIA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 183. INDIA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 184. INDIA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 185. INDIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 186. INDIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 187. INDIA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 188. INDIA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 189. INDIA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 190. INDIA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 191. INDIA IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 192. INDIA IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 193. INDONESIA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 194. INDONESIA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 195. INDONESIA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 196. INDONESIA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 197. INDONESIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 198. INDONESIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 199. INDONESIA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 200. INDONESIA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 201. INDONESIA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 202. INDONESIA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 203. INDONESIA IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 204. INDONESIA IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 205. JAPAN IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 206. JAPAN IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 207. JAPAN IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 208. JAPAN IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 209. JAPAN IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 210. JAPAN IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 211. JAPAN IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 212. JAPAN IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 213. JAPAN IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 214. JAPAN IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 215. JAPAN IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 216. JAPAN IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 217. MALAYSIA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 218. MALAYSIA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 219. MALAYSIA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 220. MALAYSIA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 221. MALAYSIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 222. MALAYSIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 223. MALAYSIA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 224. MALAYSIA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 225. MALAYSIA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 226. MALAYSIA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 227. MALAYSIA IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 228. MALAYSIA IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 229. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 230. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 232. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 234. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 235. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 236. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 237. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 238. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 239. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 240. PHILIPPINES IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 241. SINGAPORE IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 242. SINGAPORE IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 243. SINGAPORE IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 244. SINGAPORE IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 245. SINGAPORE IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 246. SINGAPORE IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 247. SINGAPORE IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 248. SINGAPORE IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 249. SINGAPORE IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 250. SINGAPORE IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 251. SINGAPORE IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 252. SINGAPORE IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 253. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 254. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 255. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 256. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 258. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 259. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 260. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 261. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 262. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 263. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 264. SOUTH KOREA IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 265. TAIWAN IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 266. TAIWAN IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 267. TAIWAN IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 268. TAIWAN IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 269. TAIWAN IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 270. TAIWAN IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 271. TAIWAN IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 272. TAIWAN IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 273. TAIWAN IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 274. TAIWAN IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 275. TAIWAN IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 276. TAIWAN IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 277. THAILAND IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 278. THAILAND IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 279. THAILAND IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 280. THAILAND IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 281. THAILAND IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 282. THAILAND IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 283. THAILAND IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 284. THAILAND IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 285. THAILAND IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 286. THAILAND IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 287. THAILAND IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 288. THAILAND IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 289. VIETNAM IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 290. VIETNAM IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 291. VIETNAM IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 292. VIETNAM IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 293. VIETNAM IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 294. VIETNAM IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 295. VIETNAM IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 296. VIETNAM IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 297. VIETNAM IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 298. VIETNAM IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 299. VIETNAM IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 300. VIETNAM IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 314. EUROPE, MIDDLE EAST & AFRICA IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 315. DENMARK IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 316. DENMARK IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 317. DENMARK IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 318. DENMARK IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 319. DENMARK IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 320. DENMARK IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 321. DENMARK IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 322. DENMARK IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 323. DENMARK IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 324. DENMARK IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 325. DENMARK IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 326. DENMARK IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 327. EGYPT IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 328. EGYPT IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 329. EGYPT IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 330. EGYPT IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 331. EGYPT IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 332. EGYPT IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 333. EGYPT IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 334. EGYPT IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 335. EGYPT IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 336. EGYPT IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 337. EGYPT IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 338. EGYPT IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 339. FINLAND IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 340. FINLAND IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 341. FINLAND IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 342. FINLAND IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 343. FINLAND IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 344. FINLAND IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 345. FINLAND IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 346. FINLAND IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 347. FINLAND IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 348. FINLAND IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 349. FINLAND IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 350. FINLAND IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 351. FRANCE IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 352. FRANCE IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 353. FRANCE IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 354. FRANCE IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 355. FRANCE IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 356. FRANCE IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 357. FRANCE IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 358. FRANCE IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 359. FRANCE IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 360. FRANCE IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 361. FRANCE IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 362. FRANCE IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 363. GERMANY IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 364. GERMANY IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 365. GERMANY IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 366. GERMANY IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 367. GERMANY IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 368. GERMANY IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 369. GERMANY IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 370. GERMANY IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 371. GERMANY IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 372. GERMANY IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 373. GERMANY IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 374. GERMANY IMMUNOASSAY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 375. ISRAEL IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 376. ISRAEL IMMUNOASSAY MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 377. ISRAEL IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
  • TABLE 378. ISRAEL IMMUNOASSAY MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
  • TABLE 379. ISRAEL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 380. ISRAEL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 381. ISRAEL IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2018-2023 (USD MILLION)
  • TABLE 382. ISRAEL IMMUNOASSAY MARKET SIZE, BY SPECIMEN, 2024-2030 (USD MILLION)
  • TABLE 383. ISRAEL IMMUNOASSAY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 384. ISRAEL IMMUNOASSAY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 385. ISRAEL IMMUNOASSAY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 386. ISRAEL IMMUNOASSAY